Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Journal of the American College of Cardiology|August 1, 1991
Influence of balloon size and stenosis morphology on immediate and delayed elastic recoil after percutaneous transluminal coronary angioplastyC Hanet, W Wijns, X Michel, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|July 1, 1981
Contrasting effect on cardiac output of digoxin and gitoxin in humans during congestive heart failureJ Col, W Wijns, L Brasseur, et al.
European Heart Journal|July 1, 1993
Regional wall motion abnormalities in stunned and hibernating myocardiumG R Heyndrickx, W Wijns, J A Melin
Revue Medicale De Bruxelles|April 1, 1992
[Anti-phospholipid antibodies and recurrent miscarriage]P Capel, A Lambrechts, W Wijns, et al.
Circulation|September 1, 1990
Reversal of segmental hypokinesis by coronary angioplasty in patients with unstable angina, persistent T wave inversion, and left anterior descending coronary artery stenosis. Additional evidence for myocardial stunning in humansJ Renkin, W Wijns, Z Ladha, et al.
Clinical Pharmacology and Therapeutics|September 2, 2011
Optimizing revascularization strategies in coronary artery disease for optimal benefit to patientsF Mangiacapra, B De Bruyne, W Wijns, et al.
European Heart Journal|June 26, 1999
Indications for intracoronary stent placement: the european view. Working Group on Coronary Circulation of the European Society of CardiologyE Eeckhout, W Wijns, B Meier, et al.
American Heart Journal|August 1, 1991
Percutaneous transluminal coronary angioplasty of the left coronary artery in patients with chronic occlusion of the right coronary artery: clinical and functional resultsB De Bruyne, J Renkin, J Col, et al.
Circulation|July 21, 1999
Effects of dobutamine on coronary stenosis physiology and morphology: comparison with intracoronary adenosineJ Bartunek, W Wijns, G R Heyndrickx, et al.
British Journal of Clinical Pharmacology|April 1, 1986
The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonistB E Jaski, W Wijns, R Foulds, et al.
Pageof 14